Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1^-/-Ldlr^-/- mice.

ABSTRACT: Bile salts can strongly influence energy metabolism through systemic signaling, which can be enhanced by inhibiting the hepatic bile salt transporter Na⁺ taurocholate cotransporting polypeptide (NTCP), thereby delaying hepatic reuptake of bile salts to increase systemic bile salt levels. Bulevirtide is an NTCP inhibitor and was originally developed to prevent NTCP-mediated entry of Hepatitis B and D into hepatocytes. We previously demonstrated that NTCP inhibition lowers body weight, induces glucagon-like peptide-1 (GLP1) secretion, and lowers plasma cholesterol levels in murine obesity models. In humans, a genetic loss-of-function variant of NTCP has been associated with reduced plasma cholesterol levels. Here, we aimed to assess if Bulevirtide treatment attenuates atherosclero

SUBMITTER: Porteiro B 

PROVIDER: S-EPMC11382107 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature